New Nanoparticle Platform Delivers mRNA Directly to the Pancreas
Scientists engineer lipid nanoparticles that selectively accumulate in the pancreas, enabling gene editing and cancer immunotherapy with striking precision.
Summary
Researchers at Tsinghua University and Zhejiang University have developed a lipid nanoparticle platform called AH-LNP that selectively delivers mRNA to the pancreas. The system exploits a novel 'organ capsule filtration' principle: after injection, AH-LNPs enlarge by binding circulating proteins, causing them to become trapped preferentially in the pancreatic capsule. Once there, receptor-mediated endocytosis pulls them into pancreatic cells. The platform successfully delivered Cas9 mRNA and guide RNA to achieve precise genome editing in the pancreas, and separately delivered therapeutic cytokine-encoding mRNA to enhance anti-tumor immunity in pancreatic cancer models. Efficacy was validated across rodents and non-human primates, suggesting strong translational potential.
Detailed Summary
Pancreatic diseases — including pancreatic cancer and autoimmune pancreatitis — are notoriously difficult to treat partly because targeted drug delivery to the pancreas has remained elusive. Most lipid nanoparticle (LNP) systems accumulate preferentially in the liver, leaving the pancreas largely inaccessible. This landmark study published in Nature establishes a clear mechanistic principle for pancreatic-selective delivery and a practical nanoparticle system to exploit it.
The research team engineered AH-LNP, a novel lipid nanoparticle formulation that undergoes size enlargement after assembling with endogenous serum proteins in circulation. This protein corona-driven enlargement enables the particles to become selectively filtered and retained by the pancreatic organ capsule — a passive anatomical mechanism the authors term 'organ capsule filtration.' Subsequent receptor-mediated endocytosis then draws the particles into pancreatic cells, achieving high intracellular delivery.
In proof-of-concept experiments, AH-LNP delivered CRISPR-Cas9 mRNA and single guide RNA (sgRNA) to achieve efficient, precise genome editing specifically within the pancreas. This approach showed therapeutic promise for autoimmune pancreatic diseases. Separately, AH-LNP loaded with mRNA encoding therapeutic cytokines demonstrated potent anti-tumor activity when combined with a cancer vaccine or CAR-T cell therapy across multiple pancreatic cancer models.
Critically, the platform was tested in non-human primates, where pancreatic mRNA delivery and safety profiles were confirmed — a significant step toward clinical translation. A patent has been filed by Tsinghua University, reflecting the commercial significance of this discovery.
Caveats include the fact that only the abstract is available, limiting granular assessment of experimental design. Long-term safety, immunogenicity of repeated dosing, and manufacturing scalability remain open questions that must be addressed before human trials.
Key Findings
- AH-LNPs selectively accumulate in the pancreas via a protein corona-driven size enlargement and organ capsule filtration mechanism.
- CRISPR-Cas9 mRNA and sgRNA delivered by AH-LNP achieved precise genome editing in pancreatic tissue.
- Cytokine mRNA delivery via AH-LNP enhanced anti-tumor efficacy in multiple pancreatic cancer models when combined with vaccines or CAR-T therapy.
- Pancreatic targeting and safety were validated in non-human primates, supporting clinical translatability.
- The organ capsule filtration principle may represent a universal framework for selective organ targeting beyond the pancreas.
Methodology
The study used AH-LNP nanoparticles engineered to exploit protein corona-mediated size changes for pancreatic capsule filtration, validated in rodent models and non-human primates. Therapeutic applications tested include CRISPR genome editing and cytokine mRNA delivery in pancreatic cancer and autoimmune disease models. Only the abstract was available for this analysis; full experimental details were not accessible.
Study Limitations
Only the abstract was available, limiting detailed evaluation of controls, dosing, and statistical methodology. Long-term safety, immunogenicity of repeated AH-LNP dosing, and large-scale manufacturing feasibility have not yet been reported. The competing interest disclosure (patent held by lead authors) warrants independent replication before clinical adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: